Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case–Control Study

Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based... Cardiol Ther (2015) 4:65–76 DOI 10.1007/s40119-015-0035-1 ORIGINAL RESEARCH Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case–Control Study • • Henry W. C. Leung Li-Ling Hung Agnes L. F. Chan Chih-Hsin Mou To view enhanced content go to www.cardiologytherapy-open.com Received: December 22, 2014 / Published online: February 6, 2015 The Author(s) 2015. This article is published with open access at Springerlink.com types of antihypertensive drugs, statins and co- ABSTRACT morbidities. Introduction: To evaluate the risk of breast Results: Among the AHs used to treat the cancer associated with long-term use of hypertensive women enrolled in our study, antihypertensive agents (AHs) in Taiwanese our analysis revealed that those treated with women with hypertension. one specific particular class of beta-blockers Methods: A search of the Taiwan National (beta-1 selective beta-blockers) had an Health Insurance Research Database identified increased risk for breast cancer. We also found 330,699 patients with hypertension who were that the ever-use of calcium channel blockers treated with antihypertensive drugs between (CCBs; i.e. for 13 years) was associated with January 1, 1998 and December 31, 2011. breast cancer in an adjusted model (OR 1.09; Logistic regression models were used to 95% CI 1.03–1.16). However, the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case–Control Study

Download PDF
12 pages

Loading next page...
 
/lp/springer-journals/long-term-use-of-antihypertensive-agents-and-risk-of-breast-cancer-a-rQIcX9sP5J
Publisher
Springer Journals
Copyright
Copyright © 2015 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine; Cardiology
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-015-0035-1
pmid
25657096
Publisher site
See Article on Publisher Site

Abstract

Cardiol Ther (2015) 4:65–76 DOI 10.1007/s40119-015-0035-1 ORIGINAL RESEARCH Long-Term Use of Antihypertensive Agents and Risk of Breast Cancer: A Population-Based Case–Control Study • • Henry W. C. Leung Li-Ling Hung Agnes L. F. Chan Chih-Hsin Mou To view enhanced content go to www.cardiologytherapy-open.com Received: December 22, 2014 / Published online: February 6, 2015 The Author(s) 2015. This article is published with open access at Springerlink.com types of antihypertensive drugs, statins and co- ABSTRACT morbidities. Introduction: To evaluate the risk of breast Results: Among the AHs used to treat the cancer associated with long-term use of hypertensive women enrolled in our study, antihypertensive agents (AHs) in Taiwanese our analysis revealed that those treated with women with hypertension. one specific particular class of beta-blockers Methods: A search of the Taiwan National (beta-1 selective beta-blockers) had an Health Insurance Research Database identified increased risk for breast cancer. We also found 330,699 patients with hypertension who were that the ever-use of calcium channel blockers treated with antihypertensive drugs between (CCBs; i.e. for 13 years) was associated with January 1, 1998 and December 31, 2011. breast cancer in an adjusted model (OR 1.09; Logistic regression models were used to 95% CI 1.03–1.16). However, the

Journal

Cardiology and Therapy – Springer Journals

Published: Feb 6, 2015

References

  • Pattern analysis and variations in the utilization of antihypertensive drugs in Taiwan: a six-year study
    Huang, LY; Shau, WY; Chen, HC
  • Use of antihypertensive medications and breast cancer risk among women aged 55 to 74 years
    Li, CI; Daling, JR; Tang, MT; Haugen, KL; Porter, PL; Malone, KE
  • Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort
    Ganz, PA; Habel, LA; Weltzien, EK; Caan, BJ; Cole, SW
  • Expanding our therapeutic options: beta blockers for breast cancer?
    Ganz, PA; Cole, SW
  • Targeted therapies: using beta-blockers to inhibit breast cancer progression
    Powe, DG; Entschladen, F
  • Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials
    Bangalore, S; Kumar, S; Kjeldsen, SE
  • Does beta adrenoceptor blocker therapy improve cancer survival? Findings from a population based retrospective cohort study
    Shah, SM; Carey, IM; Owen, CG; Harris, T; Dewilde, S; Cook, DG
  • Beta-blocker usage and breast cancer survival: a nested case–control study within a UK Clinical Practice Research Datalink cohort
    Cardwell, CR; Coleman, HG; Murray, LJ; Entschladen, F; Powe, DG
  • Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals
  • Use of angiotensin receptor blockers and the risk of cancer
    Pasternak, B; Svanström, H; Callréus, T; Melbye, M; Hviid, A
  • Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials
    Sipahi, I; Debanne, SM; Rowland, DY; Simon, DI; Fang, JC
  • A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
    Charlson, ME; Pompei, P; Ales, KL; MacKenzie, CR
  • Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival
    Powe, DG; Voss, MJ; Zänker, KS
  • Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer
    Melhem-Bertrandt, A; Chavez-Macgregor, M; Lei, X
  • Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells
    Drell, TL; Joseph, J; Lang, K; Manni, A
  • Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs
    Lang, K; Drell, TL; Lindecke, A; Niggemann, B; Kaltschmidt, C
  • Beta-adrenoceptor signaling and its control of cell replication in MDA-MB-231 human breast cancer cells
    Slotkin, TA; Zhang, J; Dancel, R
  • A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway
    Carie, AE; Sebti, SM
  • Beta-adrenergic and acid-mediated growth regulation of human breast cancer cell lines
    Cakir, Y; Plummer, HK; Tithof, PK; Schuller, HM
  • The sympathetic nervous system induces a metastatic switch in primary breast cancer
    Sloan, EK; Priceman, SJ; Cox, BF
  • β-Adrenergic receptors (β-AR) regulate VEGF and IL-6 production by divergent pathways in high β-AR-expressing breast cancer cell lines
    Madden, KS; Szpunar, MJ; Brown, EB
  • beta-Adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration
    Işeri, OD; Sahin, FI; Terzi, YK; Yurtcu, E; Erdem, SR; Sarialioglu, F
  • Use of antihypertensive medications and breast cancer risk
    Saltzman, BS; Weiss, NS; Sieh, W
  • Association between calcium channel blockers and breast cancer: a meta-analysis of observational studies
    Chen, Q; Zhang, Q; Zhong, F